Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.67 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enriched outside the brain (prostatic glandular cells) | 0.10 |
| chemistry Open Targets | compounds already reach it: procyclidine, trihexyphenidyl hydrochloride, cevimeline hydrochloride +50 | 1.00 |
| trials ClinicalTrials.gov | 2 Parkinson's trials, 0 stopped | 1.00 |
| literature PubMed | 5 Parkinson's papers of 185 | 0.76 |
| pathways Reactome | 2 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 11445
Earlier readings: 2026-10-26 0.43; 2026-10-25 0.43; 2026-10-24 0.43; 2026-10-23 0.43.
Sealed predictions
- CHRM1 in dopamine neurons, braak-0.20 (p 0.601) → -0.15 (p 0.705)receipt 0528
- CHRM1 in dopamine neurons, resilience-0.45 (p 0.126) → -0.07 (p 0.788)receipt 0035
- CHRM1 in dopamine neurons, braak-0.18 (p 0.255) → +0.14 (p 0.385)receipt 0034
Swarm cases
receipt 0528: CHRM1 in dopamine neurons, braak
- power
- full sample -0.36 (p 0.148, n 18), 95% CI -0.71 to +0.13. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.40 (p 0.103, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.57 (p 0.014, n 18). not the mix.
- skeptic
- leave-one-out range -0.47 to -0.27, sign flips 0; without severely affected donors -0.36 (p 0.148, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CHRM1 in dopamine neurons.
case closed: nothing better to follow up.
receipt 0035: CHRM1 in dopamine neurons, resilience
- power
- full sample -0.24 (p 0.230, n 55), 95% CI -0.47 to +0.03. the interval is wide: not enough donors to tell.
- confounder
- adjusted for age, sex and PMI: -0.26 (p 0.185, n 55). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.12 (p 0.542); controlling for it: -0.26 (p 0.178, n 55). could be the mix.
- skeptic
- leave-one-out range -0.29 to -0.18, sign flips 0; without severely affected donors -0.25 (p 0.212, n 46). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "differs in resilient donors (Lewy pathology, no parkinsonism)" for CHRM1 in dopamine neurons.
case closed: nothing better to follow up.
receipt 0034: CHRM1 in dopamine neurons, braak
- power
- full sample -0.01 (p 0.897, n 84), 95% CI -0.23 to +0.20. the interval sits on zero: probably nothing there.
- confounder
- adjusted for age, sex and PMI: -0.09 (p 0.402, n 84). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis -0.72 (p 1.8e-14); controlling for it: -0.09 (p 0.439, n 84). could be the mix.
- skeptic
- leave-one-out range -0.04 to +0.02, sign flips 14; without severely affected donors +0.00 (p 0.992, n 75). fragile.
- cell type
- strongest in OPCs: -0.31 (p 0.0043, n 84) vs -0.01 in dopamine neurons. proposing OPCs.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CHRM1 in dopamine neurons.
follow-up registered; not confirmed in ventral tegmental area.
follow-up CHRM1 · OPCs · braak: ventral tegmental area -0.10 p 0.399 (needs p < 0.0083)
Receipts
loading the receipts